124 related articles for article (PubMed ID: 33952478)
1. PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma.
Hisakane K; Seike M; Sugano T; Matsuda K; Kunugi S; Nakamichi S; Matsumoto M; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
Anticancer Res; 2021 May; 41(5):2501-2509. PubMed ID: 33952478
[TBL] [Abstract][Full Text] [Related]
2. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma.
Tsutsumi S; Saeki H; Nakashima Y; Ito S; Oki E; Morita M; Oda Y; Okano S; Maehara Y
Cancer Sci; 2017 Jun; 108(6):1119-1127. PubMed ID: 28294486
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological Features, Surgical Outcomes, Oncogenic Status and PD-L1 Expression of Pulmonary Pleomorphic Carcinoma.
Nakanishi K; Sakakura N; Matsui T; Ueno H; Nakada T; Oya Y; Shimizu J; Hida T; Hosoda W; Kuroda H
Anticancer Res; 2019 Oct; 39(10):5789-5795. PubMed ID: 31570483
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the Role and Mechanism of ZEB1 in Regulating Cervical Carcinoma Progression via Modulating PD-1/PD-L1 Checkpoint.
Lin Y; Wang X
Comput Math Methods Med; 2022; 2022():1565094. PubMed ID: 35535226
[TBL] [Abstract][Full Text] [Related]
5. Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung.
Imanishi N; Hirai A; Yoneda K; Shimajiri S; Kuwata T; Tashima Y; Takeuchi M; Iwai Y; Ichiki Y; Tanaka F
J Surg Oncol; 2018 Jun; 117(7):1563-1569. PubMed ID: 29601633
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
[TBL] [Abstract][Full Text] [Related]
7. High programmed death ligand 1 expression in carcinomatous components predicts a poor prognosis in pulmonary pleomorphic carcinoma.
Noguchi M; Menju T; Nakajima N; Yoshizawa A; Ohsumi A; Nakajima D; Hamaji M; Haga H; Date H
Surg Today; 2022 Jul; 52(7):1090-1095. PubMed ID: 35041089
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PD-L1 expression in non-small cell lung cancer may reduce vasculogenic mimicry formation by inhibiting the epithelial mesenchymal transformation process.
Shi Y; Li W; Jia Q; Wu J; Wu S; Wu S
Exp Cell Res; 2024 Apr; 437(1):113996. PubMed ID: 38508327
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
[TBL] [Abstract][Full Text] [Related]
10. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
[TBL] [Abstract][Full Text] [Related]
11. Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition.
Kwon MJ; Rho YS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Kim ES; Park B; Hong M; Min KW
Hum Pathol; 2018 Oct; 80():28-39. PubMed ID: 29634978
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Tumor Immunity in Surgically Resected Pulmonary Pleomorphic Carcinoma.
Kaira K; Shimizu K; Endoh H; Imaizumi K; Kamiyoshihara M; Sugano M; Kawashima O; Tanaka S; Fujita A; Imai H; Kogure Y; Oyama T; Asao T; Shirabe K
Anticancer Res; 2020 Jan; 40(1):261-269. PubMed ID: 31892575
[TBL] [Abstract][Full Text] [Related]
13. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
[No Abstract] [Full Text] [Related]
14. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer.
Funaki S; Shintani Y; Kawamura T; Kanzaki R; Minami M; Okumura M
Oncol Rep; 2017 Oct; 38(4):2277-2284. PubMed ID: 28849209
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of programmed cell death 1 and its ligand and the correlation with epithelial-mesenchymal transition in thymic carcinoma.
Funaki S; Shintani Y; Fukui E; Yamamoto Y; Kanzaki R; Ose N; Kanou T; Minami M; Mori E; Okumura M
Cancer Med; 2019 Jan; 8(1):216-226. PubMed ID: 30600651
[TBL] [Abstract][Full Text] [Related]
16. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive Traits of the Hybrid Epithelial/Mesenchymal Phenotype.
Sahoo S; Nayak SP; Hari K; Purkait P; Mandal S; Kishore A; Levine H; Jolly MK
Front Immunol; 2021; 12():797261. PubMed ID: 34975907
[TBL] [Abstract][Full Text] [Related]
18. High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
Chang YL; Yang CY; Lin MW; Wu CT; Yang PC
Eur J Cancer; 2016 Jun; 60():125-35. PubMed ID: 27107327
[TBL] [Abstract][Full Text] [Related]
19. Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer.
Messeha SS; Zarmouh NO; Soliman KFA
Nutrients; 2021 May; 13(5):. PubMed ID: 34069461
[TBL] [Abstract][Full Text] [Related]
20. Cytopathological and immunocytochemical findings of pancreatic anaplastic carcinoma with ZEB1 expression by means of touch imprint cytology.
Naito Y; Kawahara A; Taira T; Takase Y; Murata K; Ishida Y; Okabe Y; Tanigawa M; Mihara Y; Nakayama M; Shimamatsu K; Yano H; Akiba J
Diagn Cytopathol; 2018 Feb; 46(2):198-203. PubMed ID: 28940869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
